Form 4: Amgen Executive David M. Reese Reports Stock Disposals

EVP & Chief Technology Officer of Amgen, David M. Reese, reports disposals of common stock to cover tax obligations.

Summary

• David M. Reese, EVP & Chief Technology Officer of Amgen, filed a Form 4 detailing changes in beneficial ownership.
• The report indicates the disposal of Amgen common stock on May 2, 2025.
• 702 shares were disposed of at a price of $283.78.
• An additional 665 shares were disposed of at a price of $283.78.
• Following these transactions, Reese beneficially owns 38,567 shares of Amgen common stock.
• These shares include 397 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. Second Amended and Restated 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan.

Sentiment

Score: 5

Explanation: Neutral sentiment as the document is a standard regulatory filing detailing stock transactions. It doesn't inherently indicate positive or negative performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency into the transactions of company insiders, allowing investors to monitor executive compensation and potential alignment of interests.

Stakeholder Impact

• The stock disposal may have a minor impact on shareholders due to the increased supply of shares, but the effect is likely minimal given the relatively small number of shares involved.

Key Dates

Keywords

Form 4, Beneficial Ownership, AMGN, Amgen, David M. Reese, Stock Disposal, Executive Compensation